Skip Navigation

Human Reproduction 2008 23(12):2617-2621; doi:10.1093/humrep/den400
This Article
Right arrow Full Text
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Hum. Reprod.
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fritz, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fritz, M. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Perspectives on the efficacy and indications for preimplantation genetic screening: where are we now?

Marc A. Fritz

Division of Reproductive Endocrinology and Fertility, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, CB#7570, 4001 Old Clinic, Chapel Hill, NC 27599-7570, USA

Correspondence address. E-mail: marc_fritz@med.unc.edu

Key words: preimplantation genetic screening/aneuploidy

The first 150 words of the full text of this article appear below.

Given that the majority of failed implantations and early pregnancies reasonably may be attributed to embryo aneuploidy, the logical foundation for the use of preimplantation genetic screening (PGS) in cycles of in vitro fertilization (IVF) seems undeniably sound. If abnormal embryos having no implantation or advanced developmental potential can be identified accurately and excluded, and if only normal, euploid embryos are transferred, improved outcomes certainly should be expected, at least in women at a high risk of aneuploidy, if not in all women. Those at greatest risk of aneuploidy and therefore presumed most likely to benefit from PGS include women of advanced maternal age, women having recurrent unexplained miscarriages or implantation failure after transfer of good-quality embryos, and women with partners having severe male factor infertility.

Results of a recent randomized controlled trial evaluating the efficacy of preimplantation genetic screening (PGS) for the indication of advanced maternal age stimulated a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Hum. Reprod.:

What next for assisted reproductive technology? A plea for an evidence-based approach
André Van Steirteghem
Hum. Reprod. 2008 23: 2615-2616. [Extract] [Full Text]  



This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
G. Benagiano, S. Carrara, and V. Filippi
Sex and reproduction: an evolving relationship
Hum. Reprod. Update, September 2, 2009; (2009) dmp028v1.
[Abstract] [Full Text] [PDF]